表紙
市場調査レポート

癌治療ワクチン市場:パイプラインは安全な治療と患者生存期間の延長を示すが、高価格が普及を抑制

Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

発行 GBI Research 商品コード 268580
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
癌治療ワクチン市場:パイプラインは安全な治療と患者生存期間の延長を示すが、高価格が普及を抑制 Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
出版日: 2013年03月31日 ページ情報: 英文 115 Pages
概要

プロベンジは、現在市販されている唯一の癌治療ワクチンですが、世界における2011年の売上はおよそ2億1500万米ドルに達しました。世界の癌治療ワクチン市場は2019年までに78億米ドル額に成長する可能性を持っています。

当レポートでは、世界の癌治療ワクチン市場について調査分析し、治療利用パターン、ワクチン種類・パイプライン別の市場予測、プロベンジの分析、癌治療ワクチンパイプラインの包括的レビュー、フェーズ・ワクチン種類別の治験期間・規模の統計分析、適応症ごとの予測モデル、および市場の促進因子と阻害因子などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 癌の疫学
  • 疾患発症・増殖
  • 症状
  • 現在の治療・管理
  • ウィルス誘発性の癌・予防ワクチン
  • 癌、免疫システムおよび治療ワクチン
  • 癌治療ワクチンを開発する理由?
  • 癌治療ワクチンの種類

第3章 上市製品

  • プロベンジ:ホルモン抵抗性前立腺癌治療用の自己移植細胞免疫療法ワクチン
  • プロベンジの近年の売上・商業化
  • 現在・将来におけるプロベンジの競合製品

第4章 製品パイプライン

  • パイプライン概要

第5章 予測

  • 世界の癌治療ワクチン市場
  • 結腸直腸癌
  • 多形性膠芽腫
  • リンパ腫
  • メラノーマ
  • 非小細胞肺癌
  • 膵臓癌
  • 前立腺癌
  • 癌治療ワクチン市場の促進因子と阻害因子

第6章 付録

図表

目次
Product Code: GBIHC271MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake". There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬-resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011. Over the forecast period, numerous vaccines are anticipated to be approved over a range of indications including the commonly diagnosed lung and colorectal cancer types. All of these vaccines have been shown to improve patient survival, some by a few months, others by years. The high anticipated price tag of these vaccines will be a barrier of market growth. However, due to the fact that numerous vaccines are anticipated to be approved across a range of highly diagnosed indications, GBI Research believes the global market does have the potential to grow to a value of $7.8 billion by 2019.

Scope

  • The report analyzes treatment usage patterns, variation in vaccine type and pipeline and market forecasts across indications for cancer vaccines.
  • A brief introduction into cancer, its relation with the immune system, and a detailed outline of the 8 different types of cancer vaccines being developed, including their strengths and weaknesses.
  • An analysis of Provenge, the only currently marketed therapeutic cancer vaccines, including recent sales figures and potential future competitors of Provenge.
  • Comprehensive reviews of the pipeline for therapeutic cancer vaccines with individual analyses on the most heavily researched and most common cancers of melanoma, breast, prostate, colorectal, stomach and Non-small-cell lung cancer. The analyses include the phase distribution, the most common type of vaccine and most frequently observed molecular target for each indication.
  • A statistical analysis of clinical trial duration and size by phase and by vaccine type.
  • An in depth forecast model for each indication for which a vaccine is anticipated to be approved throughout the forecast period. Each model is based on the anticipated market performance of the vaccines to be approved for that indication.
  • A detailed discussion of the drivers and barriers for this novel market.

Reasons to buy

  • The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
  • Understand the variation in the types of therapeutic cancer vaccines, and the strength and weaknesses of each form.
  • Understand the vast scope of the pipeline, including which vaccine types and molecular targets are generating the most interest.
  • Observe the trends in clinical trial duration and size amongst Phases and vaccine types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for therapeutic cancer vaccines.
  • Observe the shift in clinical trial endpoints with Phase, and use this data to potentially influence any future developmental programs.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the therapeutic cancer vaccines market.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Cancer Epidemiology
  • 2.2. Disease Initiation and Propagation
  • 2.3. Symptoms
    • 2.3.1. Symptoms of Lung Cancer
    • 2.3.2. Symptoms of Prostate Cancer
    • 2.3.3. Symptoms of Colorectal Cancer
    • 2.3.4. Symptoms of Breast Cancer
    • 2.3.5. Symptoms of Melanoma
    • 2.3.6. Symptoms of Stomach Cancer
  • 2.4. Current Treatment and Management
    • 2.4.1. Active Surveillance or the 'Wait-and See' Approach
    • 2.4.2. Surgery
    • 2.4.3. Radiation Therapy
    • 2.4.4. Chemotherapy
    • 2.4.5. Targeted Therapy
    • 2.4.6. Hormone Therapy
    • 2.4.7. Immunotherapy
  • 2.5. Virally Induced Cancers and Prophylactic Vaccines
  • 2.6. Cancer, the Immune system and Therapeutic Vaccines
    • 2.6.1. Mechanisms of Immune System Evasion
    • 2.6.2. Mechanisms of Immune System Disabling
  • 2.7. Why Develop Therapeutic Cancer Vaccines?
  • 2.8. Types of Therapeutic Cancer Vaccine
    • 2.8.1. Anti-Idiotype Vaccines
    • 2.8.2. Whole-Cell-Derived Vaccines
    • 2.8.3. Cellular Immunotherapy
    • 2.8.4. Antigen-Based Vaccines
    • 2.8.5. DNA-Based Vaccines
    • 2.8.6. Vector-Based (Microorganism-Facilitated) Vaccines
    • 2.8.7. Oncolytic Virus Vaccines
    • 2.8.8. Adjuvants

3. Marketed Products

  • 3.1. Provenge - an Autologous Cellular Immunotherapy Vaccine for the Treatment of Hormone-Refractory Prostate Cancer
    • 3.1.1. Overview
    • 3.1.2. Mechanism of Action and Molecular Target
    • 3.1.3. Formulation and Dosing
    • 3.1.4. Provenge within the Clinical Landscape for Prostate Cancer
    • 3.1.5. Company Profile and Patent Expiry
  • 3.2. Recent Sales and Commercialization of Provenge
  • 3.3. Current and Future Market Competitors for Provenge

4. Product Pipeline

  • 4.1. Pipeline Overview
    • 4.1.1. Developmental Pipeline of all Major Indications
    • 4.1.2. Clinical Trials
    • 4.1.3. Clinical Trial Failure
    • 4.1.4. Key Companies Developing Cancer Vaccines
    • 4.1.5. Promising Drugs in the Developmental Pipeline

5. Forecasting

  • 5.1. Therapeutic Cancer Vaccines Market to 2019 - Global
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Annual Cost of Treatment
  • 5.2. Colorectal Cancer
    • 5.2.1. Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Glioblastoma Multiforme
    • 5.3.1. Emerging Cancer Vaccines and their Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Lymphoma
    • 5.4.1. Emerging Cancer Vaccines for Lymphoma and their Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Revenues
  • 5.5. Melanoma
    • 5.5.1. Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Non-Small-Cell Lung Cancer
    • 5.6.1. Emerging Vaccines and Treatment Usage Patterns
    • 5.6.2. Annual Cost of Therapy
    • 5.6.3. Market Size
  • 5.7. Pancreatic Cancer
    • 5.7.1. Emerging Cancer Vaccines and their Market Impact
    • 5.7.2. Annual Cost of Therapy
    • 5.7.3. Market Revenues
  • 5.8. Prostate Cancer
    • 5.8.1. Treatment Usage Patterns and the Impact of Emerging Vaccines
    • 5.8.2. Annual Cost of Treatment
    • 5.8.3. Market Revenues
  • 5.9. Drivers and Barriers for Therapeutic Cancer Vaccines Market
    • 5.9.1. Drivers
    • 5.9.2. Barriers

6. Appendix

  • 6.1. Provenge Clinical Trial Titles (Table 3)
  • 6.2. Predicated Annual Cost of Therapy
    • 6.2.1. Colon Cancer
    • 6.2.2. Glioblastoma Multiforme
    • 6.2.3. Lymphoma
    • 6.2.4. Melanoma
    • 6.2.5. Non-Small-Cell Lung Cancer
    • 6.2.6. Pancreatic Cancer
    • 6.2.7. Prostate Cancer
  • 6.3. Predicted Market Forecasts
    • 6.3.1. Colon Cancer
    • 6.3.2. Glioblastoma Multiforme
    • 6.3.3. Lymphoma
    • 6.3.4. Melanoma
    • 6.3.5. Non-Small-Cell Lung Cancer
    • 6.3.6. Pancreatic Cancer
    • 6.3.7. Prostate
  • 6.4. All Pipeline Drugs by Phase
    • 6.4.1. Discovery
    • 6.4.2. Preclinical
    • 6.4.3. IND-Filed and Phase 0
    • 6.4.4. Phase I
    • 6.4.5. Phase II
    • 6.4.6. Phase III
  • 6.5. Market Definitions
  • 6.6. Abbreviations
  • 6.7. Sources
  • 6.8. Research Methodology
    • 6.8.1. Coverage
    • 6.8.2. Secondary Research
    • 6.8.3. Primary Research
    • 6.8.4. Therapeutic Landscape
    • 6.8.5. Epidemiology-Based Forecasting
    • 6.8.6. Analogous Forecasting Methodology
    • 6.8.7. Diseased Population
    • 6.8.8. Prescription Population
  • 6.9. Market Size by Geography
    • 6.9.1. Forecasting Model for Therapeutic Areas
  • 6.10. Geographical Landscape
  • 6.11. Pipeline Analysis
  • 6.12. Expert Panel Validation
  • 6.13. Contact Us
  • 6.14. Disclaimer

List of Tables

  • Table 1: Therapeutic Cancer Vaccines Market, Infectious Agents and Associated Cancer(s), 2011
  • Table 2: Dendreon Corporation, Global, Provenge, Revenue ($m), 2010-2011
  • Table 3: Therapeutic Cancer Vaccines Market, Provenge, Clinical Trials upto 2012
  • Table 4: Therapeutic Cancer Vaccines Market, Safety, Efficacy and Annual Cost of Therapy of Provenge, DCVax-Prostate and Prostvac, 2013-2019
  • Table 5: Therapeutic Cancer Vaccines Market, Global, Common Molecular Targets, 2013
  • Table 6: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, 1998-2012
  • Table 7: Therapeutic Cancer Vaccines Market, Global, Key Companies, 2013
  • Table 8: Therapeutic Cancer Vaccines Market, Global, Allovectin, Phase II Clinical Trial Results, up to 2012
  • Table 9: Therapeutic Cancer Vaccines Market, Global, Lucanix, Phase II Clinical Trial Results, 2006
  • Table 10: Therapeutic Cancer Vaccines Market, Global, Safety and Efficacy of Common Adjuvant Treatment Regimes for Glioblastoma Multiforme
  • Table 11: Therapeutic Cancer Vaccines Market, Global, Cost, Safety and Efficacy of Potential Adjuvant Chemotherapy Regimens for Stage II Colon Cancer
  • Table 12: Therapeutic Cancer Vaccines Market, Global, Safety and Efficacy of Adjuvant Chemotherapy Regimens for Glioblastoma Multiforme
  • Table 13: Therapeutic Cancer Vaccines Market, Global, Common Metastatic Melanoma Treatments and Vaccines Expected to be Approved, Safety and Efficacy,
  • Table 14: Colon Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019
  • Table 15: Glioblastoma Multiforme, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019
  • Table 16: Lymphoma, Global, Predicted Annual Cost of Therapy ($'000), 2013-2019
  • Table 17: Melanoma, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019
  • Table 18: Non-Small-Cell Lung Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2014-2018
  • Table 19: Pancreatic Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2015-2019
  • Table 20: Prostate Cancer, Global, Predicted Annual Cost of Therapy ($'000), 2013-2019
  • Table 21: Colon Cancer, Global, Predicted Market Revenues ($m), 2015-2019
  • Table 22: Glioblastoma Multiforme, Global, Predicted Market Revenues ($m), 2015-2019
  • Table 23: Lymphoma, Global, Predicted Market Revenues ($m), 2013-2019
  • Table 24: Melanoma, Global, Predicted Market Revenues ($m), 2015-2019
  • Table 25: Non-Small-Cell Lung Cancer, Global, Predicted Market Revenues ($m), 2014-2019
  • Table 26: Pancreatic Cancer, Global, Predicted Market Revenues ($m), 2015-2019
  • Table 27: Prostate Cancer, Global, Predicted Market Revenues ($m), 2013-2019
  • Table 28: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Discovery Phase
  • Table 29: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Preclinical Phase
  • Table 30: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase 0 or IND-Filed
  • Table 31: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase I
  • Table 32: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase II
  • Table 33: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase III

List of Figures

  • Figure 1: Therapeutic Cancer Vaccines Market, Global, Common Cancers and Incidence Rates, 2008
  • Figure 2: Therapeutic Cancer Vaccines Market, Global, Pipeline Overview (%), 2013
  • Figure 3: Therapeutic Cancer Vaccines Market, Global, Pipeline by Indication, Incidence by Indication (million), 2013
  • Figure 4: Therapeutic Cancer Vaccines Market, Global, Lung Cancer, Pipeline Overview, 2013
  • Figure 5: Therapeutic Cancer Vaccines Market, Globa, Breast Cancer, Pipeline Overview, 2013
  • Figure 6: Therapeutic Cancer Vaccines Market, Global, Colorectal Cancer, Pipeline Overview, 2013
  • Figure 7: Therapeutic Cancer Vaccines Market, Global, Stomach Cancer, Pipeline Overview, 2013
  • Figure 8: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Pipeline Overview, 2013
  • Figure 9: Therapeutic Cancer Vaccines Market, Global, Melanoma, Pipeline Overview, 2012
  • Figure 10: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Duration (months), 1998-2012
  • Figure 11: Therapeutic Cancer Vaccines Market, Global, Cumulative Clinical Trial Duration (months), 1998-2012
  • Figure 12: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Size by Phase and Vaccine Type, 1998-2012
  • Figure 13: Therapeutic Cancer Vaccines Market, Global, Primary and Secondary Endpoints, Pipeline, 1998-2012
  • Figure 14: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Failure, Pass and Inferred Pass Rates, 2006-2012
  • Figure 15: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Failure, 1998-2012
  • Figure 16: Therapeutic Cancer Vaccines Market, Global, Revenue Forecast ($bn), 2013-2019
  • Figure 17: Therapeutic Cancer Vaccines Market, Global, Colon Cancer, Target Market ('000) and Annual Cost of Therapy ($'000) Forecast, 2015-2019
  • Figure 18: Therapeutic Cancer Vaccines Market, Global, Colon Cancer, Revenue Forecast ($m), 2015-2019
  • Figure 19: Therapeutic Cancer Vaccines Market, Global, Glioblastoma Multiforme, Target Market ('000) and Annual Cost of Therapy ($'000) Forecast, 2015-2019
  • Figure 20: Therapeutic Cancer Vaccines Market, Global, Glioblastoma Multiforme, Revenue Forecast ($m), 2015-2019
  • Figure 21: Therapeutic Cancer Vaccines Market, Global, Lymphoma, Annual Cost of Therapy ($'000) and Target Market ('000), 2013-2019
  • Figure 22: Therapeutic Cancer Vaccines Market, Global, Lymphoma, Revenue Forecast ($m), 2013-2019
  • Figure 23: Therapeutic Cancer Vaccines Market, Global, Melanoma, Annual Cost of Therapy ($'000) and Target Market ('000), 2015-2019
  • Figure 24: Therapeutic Cancer Vaccines Market, Global, Melanoma, Revenue Forecast ($m), 2015-2019
  • Figure 25: Therapeutic Cancer Vaccines Market, Global, Non-Small-Cell Lung Cancer, Annual Cost of Therapy ($'000) and Target Market ('000), 2014-2019
  • Figure 26: Therapeutic Cancer Vaccines Market, Global, Non-Small-Cell Lung Cancer, Annual Cost of Therapy ($'000) and Target Market ('000), 2014-2019
  • Figure 27: Therapeutic Cancer Vaccines Market, Global, Pancreatic Cancer, Annual Cost of Treatment ($'000) and Target Market ('000), 2015-2019
  • Figure 28: Therapeutic Cancer Vaccines Market, Global, Pancreatic Cancer, Revenue Forecast ($m), 2015-2019
  • Figure 29: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Annual Cost of Treatment ($'000) and Target Market ('000), 2013-2019
  • Figure 30: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Revenue Forecast ($m), 2013-2019
  • Figure 31: GBI Research Market Forecasting Model
Back to Top